Head-To-Head Survey: 111 (NASDAQ:YI) and HeartSciences (NASDAQ:HSCS)

111 (NASDAQ:YI) and HeartSciences (NASDAQ:HSCS) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, valuation, analyst recommendations, earnings, institutional ownership, risk and dividends.

Profitability

This table compares 111 and HeartSciences’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
111	-0.76%	N/A	-3.80%
HeartSciences	N/A	-275.02%	-137.21%

Risk and Volatility

111 has a beta of 0.63, meaning that its share price is 37% less volatile than the S&P 500. Comparatively, HeartSciences has a beta of 1.78, meaning that its share price is 78% more volatile than the S&P 500.

Earnings and Valuation

This table compares 111 and HeartSciences”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
111	$1.80 billion	0.02	-$9.65 million	($1.40)	-2.69
HeartSciences	N/A	N/A	-$8.77 million	($4.94)	-0.48

HeartSciences has lower revenue, but higher earnings than 111. 111 is trading at a lower price-to-earnings ratio than HeartSciences, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of current ratings and target prices for 111 and HeartSciences, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
111	1	0	0	0	1.00
HeartSciences	1	0	1	0	2.00

HeartSciences has a consensus price target of $8.00, indicating a potential upside of 234.73%. Given HeartSciences’ stronger consensus rating and higher probable upside, analysts plainly believe HeartSciences is more favorable than 111.

Institutional and Insider Ownership

21.3% of 111 shares are held by institutional investors. Comparatively, 17.2% of HeartSciences shares are held by institutional investors. 43.9% of 111 shares are held by insiders. Comparatively, 4.9% of HeartSciences shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Summary

HeartSciences beats 111 on 7 of the 13 factors compared between the two stocks.

About 111

111, Inc. engages in the provision of pharmaceutical products and medical services through online retail pharmacy and indirectly through offline pharmacy network. It operates through the B2C and B2B segments. The B2C segment engages in the sale of pharmaceutical and other health and wellness products directly to consumers through 1 Drugstore and its offline pharmacies. The B2B segment includes the sale of pharmaceutical products to pharmacy customers through 1 Drug Mall. The company was founded by Gang Yu and Jun Ling Liu in May 2013 and is headquartered in Shanghai, China.

About HeartSciences

Heart Test Laboratories, Inc., a medical technology company, provides cardiovascular diagnostic devices. The company offers MyoVista wavECG, a resting 12-lead electrocardiograph (ECG) to provide diagnostic information related to cardiac dysfunction, as well as conventional ECG information. It serves clinics, doctor's offices, urgent care centers, and hospitals. The company was incorporated in 2007 and is headquartered in Southlake, Texas.